Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on May 14, 2024. The filing reports on corporate governance actions taken by the Board of Directors regarding equity compensation for directors and executive officers.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the exercise price for newly granted stock options, set at $9.92 per share.
Material Changes
The material change reported is the approval and issuance of stock options under the Company's 2021 Stock Incentive Plan:
- Non-Employee Directors: Each director received an option to purchase 12,500 shares. These options vest monthly (1/12) over one year and expire on May 13, 2034.
- Chief Executive Officer (Ramond J. Tesi) and Chief Financial Officer (David Moss): Each received an option to purchase 160,000 shares under incentive stock option agreements.
- Chief Scientific Officer (Mark Lowdell): Received an option to purchase 100,000 shares under a nonqualified stock option agreement.
- Executive Vesting Schedule: For the executive officers, 25% of the options vest after 12 months, with the remainder vesting monthly over the subsequent three years (total 4-year vesting period). All expire on May 13, 2034.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, management commentary on business strategy, or specific risk factors. It strictly details the terms of the equity grants and references the attached option agreements (Exhibits 10.1 and 10.2) for complete legal terms.
Investor Verification Checklist
- Verify the total number of shares reserved in the 2021 Stock Incentive Plan to assess remaining capacity for future grants.
- Review the attached Exhibit 10.1 (Nonqualified Option Agreement) and Exhibit 10.2 (Incentive Stock Option Agreement) for specific acceleration clauses or termination conditions.
- Confirm the impact of these grants on potential dilution to existing shareholders.
- Check the Company's most recent 10-Q or 10-K for current cash position and burn rate, as this 8-K does not provide liquidity data.